ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد

Epinephrine (adrenaline) decongestant (nasal): Drug information

Epinephrine (adrenaline) decongestant (nasal): Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
Special Alerts
Epinephrine Nasal Solution Safety Alert January 2025

The FDA is warning health care providers not to use unapproved epinephrine nasal solutions manufactured by BPI Labs LLC and Endo USA due to confusion with FDA-approved injectable epinephrine products. Similar packaging and containers make it difficult to distinguish the products, which can lead to accidental injection of the non-sterile nasal solution.

Further information, including recall status of the unapproved nasal solutions, can be found at https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-health-care-professionals-not-use-epinephrine-nasal-solutions-bpi-labs-and-endo-usa

Brand Names: US
  • Adrenalin
Brand Names: Canada
  • Adrenalin
Pharmacologic Category
  • Alpha-/Beta- Agonist
Dosing: Adult

Dosage guidance:

Safety: Epinephrine nasal decongestant solution (1 mg/mL) is not approved for treatment of anaphylaxis. More concentrated epinephrine nasal sprays (1 mg per 0.1 mL and 2 mg per 0.1 mL [Neffy]) are indicated for treatment of anaphylaxis; refer to Epinephrine (Systemic) for detailed information on anaphylaxis.

Anaphylaxis and other severe immediate hypersensitivity reactions

Anaphylaxis and other severe immediate hypersensitivity reactions: A concentrated epinephrine nasal spray (1 mg per 0.1 mL, 2 mg per 0.1 mL [Neffy]) is approved for the treatment of anaphylaxis; refer to Epinephrine (Systemic) monograph for detailed information.

Nasal decongestant

Nasal decongestant: Intranasal: Apply 1 mg/mL solution locally as drops or spray or with sterile swab as needed.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Epinephrine (adrenaline) decongestant (nasal): Pediatric drug information")

Dosage guidance:

Safety: Epinephrine nasal decongestant solution (1 mg/mL) is not approved for treatment of anaphylaxis. A more concentrated epinephrine nasal spray (1 mg/0.1 mL or 2 mg/0.1 mL [Neffy]) is indicated for anaphylaxis; refer to Epinephrine (Systemic) for detailed information on anaphylaxis.

Nasal congestion

Nasal congestion: Children ≥6 years and Adolescents: Intranasal: 1 mg/mL topical solution: Apply locally as drops or spray or with sterile swab; may also further dilute prior to application; consult product specific labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

Postmarketing: Cardiovascular: Cardiomyopathy (Naddaf 2020)

Warnings/Precautions

Disease-related concerns:

• Cardiovascular disease: Use with caution in patients with cardiovascular diseases (eg, coronary artery disease, hypertension).

• Cerebrovascular disease: Use with caution in patients with cerebrovascular disease.

• Diabetes: Use with caution in patients with diabetes mellitus; may transiently increase blood glucose levels.

• Parkinson disease: Use with caution in patients with Parkinson disease; may cause temporary worsening of symptoms.

• Thyroid disease: Use with caution in patients with thyroid disease.

Special populations:

• Older adult: Use with caution in older adults.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Nasal, as hydrochloride:

Adrenalin: 0.1% (30 mL)

Generic: 0.1% (10 mL, 30 mL)

Generic Equivalent Available: US

Yes

Pricing: US

Solution (Adrenalin Nasal)

0.1% (per mL): $10.02

Solution (EPINEPHrine HCl (Nasal) Nasal)

0.1% (per mL): $10.00

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Nasal, as hydrochloride:

Adrenalin: 0.1% (30 mL) [contains chlorobutanol (chlorobutol), sodium metabisulfite]

Administration: Adult

Intranasal: May be diluted with isotonic saline for a less concentrated solution (refer to manufacturer's labeling).

Note: Epinephrine nasal decongestant solution (1 mg/mL) is not approved for treatment of anaphylaxis. More concentrated epinephrine nasal sprays (1 mg per 0.1 mL and 2 mg per 0.1 mL [Neffy]) are indicated for anaphylaxis; refer to Epinephrine (Systemic) for detailed information on anaphylaxis.

Administration: Pediatric

Note: Epinephrine nasal solution (1 mg/mL) is not approved for emergency treatment of anaphylaxis. A more concentrated epinephrine nasal spray (Neffy [1 mg/0.1 mL or 2 mg/0.1 mL]) is indicated for treatment of anaphylaxis; refer to Epinephrine (Systemic) for detailed information on anaphylaxis.

Intranasal: May administer undiluted or diluted in NS. Apply as drops or with sterile swab.

Use: Labeled Indications

Nasal decongestant (nasal solution [Adrenalin]): Treatment of nasal congestion.

Note: Epinephrine nasal decongestant solution (1 mg/mL) is not approved for treatment of anaphylaxis. More concentrated epinephrine nasal sprays (1 mg per 0.1 mL and 2 mg per 0.1 mL [Neffy]) are indicated for anaphylaxis; refer to Epinephrine (Systemic) for detailed information on anaphylaxis.

Medication Safety Issues
Sound-alike/look-alike issues:

EPINEPHrine may be confused with ePHEDrine

Neffy (nasal spray) may be confused with nalaxone (nasal sprays [Kloxxado, Narcan, Rextovy, ReVive])

Metabolism/Transport Effects

Substrate of COMT;

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Alpha1-Blockers: May decrease therapeutic effects of Alpha-/Beta-Agonists. Risk C: Monitor

Atomoxetine: May increase hypertensive effects of Sympathomimetics. Atomoxetine may increase tachycardic effects of Sympathomimetics. Risk C: Monitor

Beta-Blockers (Beta1 Selective): May decrease therapeutic effects of EPINEPHrine (Nasal). Risk C: Monitor

Beta-Blockers (Nonselective): May increase hypertensive effects of EPINEPHrine (Nasal). Risk C: Monitor

Beta-Blockers (with Alpha-Blocking Properties): May decrease therapeutic effects of EPINEPHrine (Nasal). Risk C: Monitor

Bornaprine: Sympathomimetics may increase anticholinergic effects of Bornaprine. Risk C: Monitor

Bromocriptine: May increase hypertensive effects of Alpha-/Beta-Agonists. Management: Consider alternatives to this combination when possible. If combined, monitor for hypertension and tachycardia, and do not coadminister these agents for more than 10 days. Risk D: Consider Therapy Modification

Cannabinoid-Containing Products: May increase tachycardic effects of Sympathomimetics. Risk C: Monitor

Chloroprocaine (Systemic): May increase hypertensive effects of Alpha-/Beta-Agonists. Risk C: Monitor

Cocaine (Topical): May increase hypertensive effects of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Risk D: Consider Therapy Modification

COMT Inhibitors: May increase serum concentration of COMT Substrates. Risk C: Monitor

Dihydralazine: Sympathomimetics may decrease therapeutic effects of Dihydralazine. Risk C: Monitor

Doxofylline: Sympathomimetics may increase adverse/toxic effects of Doxofylline. Risk C: Monitor

Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): May increase vasoconstricting effects of Alpha-/Beta-Agonists. Risk X: Avoid

Esketamine (Injection): May increase adverse/toxic effects of Sympathomimetics. Specifically, the risk for elevated heart rate, hypertension, and arrhythmias may be increased. Risk C: Monitor

Guanethidine: May increase hypertensive effects of Sympathomimetics. Guanethidine may increase arrhythmogenic effects of Sympathomimetics. Risk C: Monitor

Hexoprenaline: May increase adverse/toxic effects of Alpha-/Beta-Agonists. Risk X: Avoid

Inhalational Anesthetics: May increase arrhythmogenic effects of EPINEPHrine (Nasal). Risk C: Monitor

Kratom: May increase adverse/toxic effects of Sympathomimetics. Risk X: Avoid

Levothyroxine: May increase therapeutic effects of Sympathomimetics. Sympathomimetics may increase therapeutic effects of Levothyroxine. Levothyroxine may increase adverse/toxic effects of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Risk C: Monitor

Linezolid: May increase hypertensive effects of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid. Risk D: Consider Therapy Modification

Lisuride: May increase hypertensive effects of Alpha-/Beta-Agonists. Risk X: Avoid

Pergolide: May increase hypertensive effects of Alpha-/Beta-Agonists. Risk C: Monitor

Serotonin/Norepinephrine Reuptake Inhibitor: May increase tachycardic effects of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitor may increase vasopressor effects of Alpha-/Beta-Agonists. Management: If possible, avoid coadministration of direct-acting alpha-/beta-agonists and serotonin/norepinephrine reuptake inhibitors. If coadministered, monitor for increased sympathomimetic effects (eg, increased blood pressure, chest pain, headache). Risk D: Consider Therapy Modification

Solriamfetol: Sympathomimetics may increase hypertensive effects of Solriamfetol. Sympathomimetics may increase tachycardic effects of Solriamfetol. Risk C: Monitor

Spironolactone: May decrease vasoconstricting effects of Alpha-/Beta-Agonists. Risk C: Monitor

Sympathomimetics: May increase adverse/toxic effects of Sympathomimetics. Risk C: Monitor

Tedizolid: May increase adverse/toxic effects of Sympathomimetics. Specifically, the risk for increased blood pressure and heart rate may be increased. Risk C: Monitor

Tricyclic Antidepressants: May increase vasopressor effects of Alpha-/Beta-Agonists. Management: Avoid, if possible, the use of alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist. Risk D: Consider Therapy Modification

Pregnancy Considerations

Refer to the EPINEPHrine (Systemic) monograph.

Breastfeeding Considerations

Refer to the EPINEPHrine (Systemic) monograph.

Mechanism of Action

Stimulates alpha-, beta1-, and beta2-adrenergic receptors resulting in local vasoconstriction and relief of nasal congestion

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Local vasoconstriction (topical): 5 minutes

Duration of action: Local vasoconstriction (topical): <1 hour

Metabolism: Taken up into the adrenergic neuron and metabolized by monoamine oxidase and catechol-o-methyltransferase; circulating drug hepatically metabolized

Excretion: Urine (as inactive metabolites, metanephrine, and sulfate and hydroxy derivatives of mandelic acid, small amounts as unchanged drug)

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AU) Australia: Adrenaline;
  • (BR) Brazil: Adrenalina;
  • (CO) Colombia: Adrenalina clorhidrato;
  • (CZ) Czech Republic: Isopto ephinal;
  • (DE) Germany: Infectokrupp | Suprarenin;
  • (ES) Spain: Adrenalina level;
  • (FI) Finland: Eppy | Isopto epinal;
  • (FR) France: Eppy;
  • (GB) United Kingdom: Adrenaline | Epifrin | Eppy | Mf adrenalin | Simplene;
  • (HU) Hungary: Epinal | Eppy | Oftan adrenalin;
  • (ID) Indonesia: Adrenal;
  • (IE) Ireland: Eppy;
  • (IN) India: Epitrate;
  • (IT) Italy: Adrenalina;
  • (JP) Japan: Glaucon | Sanepi;
  • (LT) Lithuania: Isopto ephinal;
  • (LV) Latvia: Isopto ephinal;
  • (NO) Norway: Adrenalin | Adrenalin apotek ab;
  • (PL) Poland: Adrenalin hcl | Glaucon | Isopto ephinal;
  • (PR) Puerto Rico: Epifrin | Epinephrine | Glaucon;
  • (SE) Sweden: Eppy | Glaufrin;
  • (SK) Slovakia: Glaucon;
  • (TW) Taiwan: Glaucon;
  • (VE) Venezuela, Bolivarian Republic of: Epifrin
  1. Adrenalin chloride solution (epinephrine) [prescribing information]. Rochester, MI: JHP Pharmaceuticals; received March 2017.
  2. Naddaf S, Ehrenberg S, Hakim R, Mahamid M, Turgeman Y, Koren O. Epinephrine soaked tampons induced transient acute dilated cardiomyopathy during FESS procedure. BMC Cardiovasc Disord. 2020;20(1):452. doi:10.1186/s12872-020-01706-8 [PubMed 33066731]
  3. Neffy (epinephrine) nasal spray [prescribing information]. San Diego, CA: ARS Pharmaceuticals Operations Inc; March 2025.
Topic 9115 Version 197.0